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ABSTRACT
The C-X-C motif chemokine receptor type 4 (CXCR4) and the
atypical chemokine receptor 3 (ACKR3/CXCR7) are class A G
protein-coupled receptors (GPCRs). Accumulating evidence
indicates that GPCR subcellular localization, trafficking,
transduction properties, and ultimately their pathophysiolog-
ical functions are regulated by both interacting proteins
and post-translational modifications. This has encouraged
the development of novel techniques to characterize the
GPCR interactome and to identify residues subjected to
post-translational modifications, with a special focus on
phosphorylation. This review first describes state-of-the-art
methods for the identification of GPCR-interacting proteins
and GPCR phosphorylated sites. In addition, we provide an
overview of the current knowledge of CXCR4 and ACKR3
post-translational modifications and an exhaustive list of
previously identified CXCR4- or ACKR3-interacting proteins.
We then describe studies highlighting the importance of the
reciprocal influence of CXCR4/ACKR3 interactomes and
phosphorylation states. We also discuss their impact on the
functional status of each receptor. These studies suggest
that deeper knowledge of the CXCR4/ACKR3 interactomes
along with their phosphorylation and ubiquitination status
would shed new light on their regulation and pathophysio-
logical functions.
Introduction
The C-X-C chemokine receptor type 4 (CXCR4) and the
atypical chemokine receptor 3 (ACKR3), earlier referred to as
CXCR7, are class A G protein-coupled receptors (GPCRs).
Stromal cell–derived factor-1/C-X-C motif chemokine 12
(CXCL12) binds to both CXCR4 andACKR3 receptors, whereas
C-X-C motif chemokine 11 (CXCL11) binds only to the latter
and to the C-X-C chemokine receptor type 3. CXCR4 and
ACKR3 are coexpressed in various cell types [e.g., endothelial
cells (Volin et al., 1998; Berahovich et al., 2014), neurons
(Banisadr et al., 2002; Sánchez-Alcañiz et al., 2011); and glial
cells (Banisadr et al., 2002, 2016; Odemis et al., 2010)], where
they play a pivotal role in migration, proliferation, and differen-
tiation. They are also overexpressed in various tumors and
control invasion and metastasis (Sun et al., 2010; Zhao et al.,
2015; Nazari et al., 2017).
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There is now considerable evidence indicating that GPCRs
do not operate as isolated proteins within the plasma
membrane. Instead, they physically interact with numer-
ous proteins that influence their activity, trafficking,
and signal transduction properties (Bockaert et al., 2004;
Ritter and Hall, 2009; Magalhaes et al., 2012). These
include proteins canonically associated with most GPCRs,
such as G proteins, G protein-coupled receptor kinases
(GRKs) and b-arrestins, specific partner proteins, and even
GPCRs themselves. In fact, in comparison with monomers,
GPCRs can form homomers and heteromers with spe-
cific pharmacological and signal transduction properties
(Ferré et al., 2014).
Phosphorylation is another key mechanism contributing to
the regulation of GPCR functional status and signal trans-
duction (Tobin, 2008). Both canonical GRKs and other
specific protein kinases are able to phosphorylate GPCRs
at multiple sites (Luo et al., 2017), generating the so-called
GPCR phosphorylation barcode that determines b-arrestin re-
cruitment, receptor intracellular fate, and signaling outcomes
(Reiter et al., 2012).
This review will describe recent data highlighting the
influence of the CXCR4 and ACKR3 interactome on their
functional activity and signal transduction properties. A
special focus will be given to the reciprocal influence of the
interactome on CXCR4/ACKR3 phosphorylation and its im-
pact on the functional status and pathophysiological functions
of each receptor.
Methods for the Identification of GPCR-Interacting Proteins
Considerable evidence suggests that GPCRs recruit GPCR-
interacting proteins (GIPs) (Maurice et al., 2011). This
prompted investigations aimed at identifying GIPs and at
characterizing GPCR-GIP interactions, using either un-
biased or targeted approaches. In unbiased methods, no
knowledge of the GIPs is required beforehand and the
GPCR of interest is used as bait to purify unknown GIPs.
Meanwhile, targeted methods are devoted to the validation
and characterization of previously identified GPCR-GIP
interactions. Methods for identifying GIPs or characteriz-
ing GPCR-GIP interactions include genetic, biophysical,
biochemical, or proteomic approaches and are summarized
in Table 1.
Genetic Methods. The first method belonging to this class
is the yeast two-hybrid assay (Fields and Song, 1989). In this
method, the protein of interest (the bait protein) is expressed in
yeast as a fusion to the DNA-binding domain of a transcription
factor lacking the transcription activation domain. To identify
partners of this bait, a plasmid library that expresses cDNA-
encoded proteins fused to a transcription activation domain is
introduced into the yeast strain. Interaction of a cDNA-encoded
protein with the bait protein results in the activation of the
transcription factor and expression of a reporter gene, enabling
growth on specific media or a color reaction and the identifica-
tion of the cDNA encoding the target proteins. A first disad-
vantage is the loss of spatial-temporal localization of the
interaction; in fact, the yeast two-hybrid assay only captures
a snapshot of potential interactions in an artificial biologic
system. A second disadvantage is that it is not possible to
investigatemembrane-anchored proteins since the two proteins
must cross the nuclear membrane to carry the reconstituted
transcription factor to the DNA. To overcome this issue, the
membrane yeast two-hybrid assay (Stagljar et al., 1998) was
developed. In this assay, the ubiquitin protein is split into two
fragments that are fused to the two proteins of interest. The
ubiquitin C-terminal fragment is then conjugated to a tran-
scription factor that is released when the interaction occurs,
and the ubiquitin protein is reformed. However, as in the yeast
two-hybrid assay, the spatial-temporal localization of the in-
teraction is lost. A second limitation is that the ubiquitin
C-terminus carrying the transcription factor cannot be fused
to soluble proteins because they could diffuse into the nucleus.
Therefore, a mammalian version of the assay called mamma-
lian membrane two-hybrid (Petschnigg et al., 2014) was de-
veloped. The kinase substrate sensor assay (Lievens et al.,
2014), using the signal transducer and activator of transcrip-
tion 3 (STAT3) as transcription factor, can also be used for
investigating protein-protein interactions, including those in-
volving cytosolic and membrane proteins in mammalian cells.
However, the kinase substrate sensor assay cannot be used
for studying GPCR interaction with proteins involved in the
STAT3 cascade.
Biophysical Methods. Energy transfer–based methods,
such as bioluminescence and fluorescent resonance energy
transfer [BRET (Xu et al., 1999) and FRET (Clegg, 1995)]
assays, are targeted methods that are generally used to in-
vestigate previously reported interactions. The basis of both is
the transfer of energy fromadonor to anearbyacceptor (,100Å).
Their high sensitivity allows the study of weak and transient
interactions. The high spatial-temporal resolution permits accu-
rate kinetic studies for investigating interaction dynamics.
Another biophysical method, with FRET as a basis and
employed for the study of protein-protein interaction, is fluores-
cent lifetime imaging microscopy (Sun et al., 2012). The fluores-
cence lifetime is the average time that a molecule spends in the
excited state before returning to the ground state. Since in FRET
the energy transfer from the acceptor to the donor depopulates
the excited state energy of the latter, it also shortens its lifetime.
Fluorescent lifetime imagingmicroscopy can accuratelymeasure
the shorter donor lifetime that results fromFRET; thus, it allows
mapping of the spatial distribution of protein-protein interac-
tions in living cells (Sun et al., 2011). Its main advantage over
intensity-based FRET is the more accurate measurement of
FRET, because only donor signals are measured, which elimi-
nates the corrections for spectral bleed-through (Sun et al., 2011).
Its main disadvantages are the necessity of a live specimen and
the complexity of data recording and analysis.
Biochemical Methods. The proximity ligation assay
(Fredriksson et al., 2002) is another powerful targeted
method. In the direct version of the technique, two DNA
oligonucleotide-conjugated antibodies are used against the
proteins of interest. In the indirect version, secondary DNA-
conjugated antibodies are used after the proteins of interest
are targeted with an appropriate primary antibody. If the two
conjugated antibodies are close enough (30–40 nm), they can
bind together. The DNA connecting the two probes is then
amplified and hybridized with fluorophores. This allows the
visualization of the interaction in the place where it occurs, at
a single-molecule resolution. The main disadvantages of the
approach are the high costs and the necessity for specific
antibodies, which are not always available.
In the bimolecular fluorescent complementation assay
(Hu et al., 2002; Hu and Kerppola, 2003), a fluorescent protein
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is divided into two nonfluorescent fragments that are fused to
the proteins of interest. Interaction reconstitutes the entire
fluorescent protein. This method allows the direct visualization
of the interaction and can be used for soluble or membrane-
bound proteins. In addition, several interactions can be in-
vestigated in parallel through the use of different fluorescent
proteins. Since there is a delay in fluorescence formation upon
reconstitution of the fluorescent proteins, and the fluorophore
formation is irreversible, these methods are usually not well
suited for kinetic studies. To overcome these limitations, a novel
assay called NanoBiT was developed. In this assay the nano-
luciferase enzyme is divided in two subunits (LgBiT and
SmBiT), with low affinity for each other, that can be brought
together by the two interacting proteins. The lowaffinitymakes
the interaction reversible and therefore suitable for the in-
vestigation of kinetics (Duellman et al., 2017).
Proteomics Methods. Proteomic methods aim to identify
GIPs of a receptor of interest via the use of affinity purification
coupled with mass spectrometry (AP-MS). This approach is
usually employed as an unbiased method for screening
virtually all the GIPs of a GPCR of interest. Targeted versions
of the method also exist and rely on GIP identification by
Western blotting. However, the requirement for specific
antibodies seriously limits its application. Several strategies
can be used for the affinity purification step. In co-immuno-
precipitation (Co-IP), specific antibodies against the protein of
interest are used for precipitating the bait from a protein
lysate. As specific GPCR antibodies providing high immuno-
precipitation (IP) yields are rarely available, epitope-tagged
versions of the receptor of interest are often expressed in the
cell type or the organism of interest and precipitated using
antibodies against the tag. The main advantages of Co-IP are
the purification of proteins interacting with the entire re-
ceptor (whenever possible the native receptor) in living cells or
tissues and its ability to purify the entire associated protein
complex. The main limitations are the necessity for specific
antibodies to precipitate GPCRs, the loss of spatial-temporal
information, and the use of detergents for cell lysis that might
denaturate the GPCR of interest and, accordingly, disrupt
interactions with their protein partners. For this reason,
special attention must be paid to lysis conditions that
efficiently solubilize the receptor while conserving the receptor’s
native conformation and its interactionswithGIPs. For instance,
detergents such as Triton and NP-40 completely denaturate
CXCR4 (Palmesino et al., 2016), whereas 3-([3-cholamidopropyl]-
dimethylammonio)-2-hydroxy-1-propanesulfonate, also called
CHAPSO (Babcock et al., 2001), and n-dodecyl-b-D-maltopyrano-
side, also called DDM (Palmesino et al., 2016), yield the highest
proportion of receptor in the native conformation. Despite this
limitation, several CXCR4-interacting proteins have been iden-
tified using Co-IP approaches (see Table 2).
Alternatively, pull-down assays can be performed to purify
GPCR partners from a cell or tissue lysate. This approach uses
the receptor (or one of its domains) fused with an affinity tag
(e.g., glutathione-S-transferase) and immobilized on beads as
bait. Such in vitro binding assays can also be used to prove
direct physical interaction between two protein partners. In
this case, the bait is incubated with a purified protein instead of
a cell or tissue lysate. In all methods, affinity purified proteins
are systematically identified by liquid chromatography coupled
to tandemmass spectrometry (LC-MS/MS). A two-step version,
named tandem affinity purification (Puig et al., 2001), has also
been reported (Daulat et al., 2007) and applies to both Co-IPs or
pull-downs. Although tandem affinity purification methods
drastically reduce the number of false-positive identifications,
they require larger amounts of starting material.
In the proximity-dependent biotin identification method
(Roux et al., 2013), the bait protein is fused to a prokaryotic
biotin ligase molecule that biotinylates proteins in close
proximity once expressed in cells. The method can detect
weak and transient interactions occurring in living cells, and
detergents do not affect the results. Though the fusion of biotin
ligase to the bait might alter its targeting or functions,
proximity-dependent approaches were recently applied to
identify a GPCR-associated protein network with a high
temporal resolution. Specifically, engineered ascorbic acid
peroxidase was employed in combination with quantitative
proteomics to decipher b-2 adrenergic (Lobingier et al., 2017;
Paek et al., 2017) and angiotensin II type 1 (Paek et al., 2017)
receptor–interacting proteins.
Methods for the Identification of GPCR Phosphorylated
Sites
GPCR phosphorylation is a key regulatory mechanism of
receptor function (Lefkowitz, 2004). Over the past years,
numerous techniques have appeared with increasing resolu-
tion to pinpoint phosphorylated residues (summarized in
Table 1), which consist of serines, threonines, or tyrosines.
Radioactive Labeling. The first method that was in-
troduced for deciphering the phosphorylation status of GPCRs
is a radioactivity-based technique, consisting of culturing cells
in a medium in which phosphate is replaced with its radioac-
tive counterpart, 32P, resulting in radioactive phosphorylated
residues (Meisenhelder et al., 2001). After culture, cells are
lysed and receptors are immunoprecipitated using specific
antibodies, and then resolved by SDS-PAGE. Receptors can
then be digested using an enzyme such as trypsin, and the
resulting peptides are separated by two-dimensional migra-
tion using electrophoresis and chromatography. Radioactive
peptides are then detected in-gel by autoradiography or using
a phosphorimager, yielding a phosphorylation map for a given
receptor in a given cell line (Chen et al., 2013). This method is
very sensitive but does not give precise information on the
number of phosphorylated sites nor their position. Radioactive
labeling was initially employed to characterize CXCR4 phos-
phorylation upon agonist stimulation (Haribabu et al., 1997).
These studies characterized the C-terminal domain as the
preferred site for phosphorylation (Haribabu et al., 1997) and
identified a serine cluster present in the C-terminal domain
and containing two residues (Ser338, Ser339) phosphorylated
following CXCL12 challenge (Orsini et al., 1999).
LC-MS/MS. More recently, radioactive labeling-based meth-
ods have been progressively supplanted by the identification of
phosphorylated residues by LC-MS/MS. In this method, the
GPCR of interest is digested enzymatically, with one or several
proteases, to generate peptides that cover a large part of
the receptor sequence. The resulting peptides are then ana-
lyzed by LC-MS/MS (Dephoure et al., 2013). Although this
approach can pinpoint any phosphorylated residue with high
confidence, a few limitations complicate phosphorylated res-
idue identification. First, phosphorylation can be lost dur-
ing fragmentation. Second, since phosphorylation sites have a
limited level of phosphorylation, only a small percentage of
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peptide is actually phosphorylated (Wu et al., 2011). Third, the
identification of the phosphorylated residues in peptides with
multiple adjacent phosphorylated residues can be challenging.
For each modified site, a phosphorylation index can be
estimated by dividing the ion signal intensity corresponding
to the phosphorylated peptide by the sum of the ion signals of
the phosphorylated peptide and its nonphosphorylated coun-
terpart. Absolute quantification, and thus the stoichiometry of
phosphorylation, can also be determined for each modified
residue by spiking the sample with a known concentration of
high-purity, heavy isotope–labeled peptides (AQUA peptides)
that correspond to the phosphorylated peptide and not phos-
phorylated one. The respective ion signals of unlabeled and
labeled peptides are then compared (Gerber et al., 2003). This
powerful technology allowed a first comprehensive phosphory-
lationmap ofCXCR4, stimulated or notwithCXCL12 inhuman
embryonic kidney (HEK)293 cells: LC-MS/MS analyses identi-
fied six phosphorylated residues: Ser321, Ser324, Ser325, one
between Ser338/339/341, one between Ser346/347/348, and either
Ser351 or Ser352 (Busillo et al., 2010).
Mutagenesis. Another approach that can be used as a stand-
alone technique or in complement with the previously described
methods is to mutate potential or predicted phosphorylated
residues (into alanine or aspartate to inhibit or mimic their
phosphorylation, respectively) and assess functional differences
between mutated and wild-type receptor (Okamoto and Shikano,
2017). Nevertheless, introducing those mutations can potentially
alter expression of the receptor, its conformation, or its cellular
localization. Despite these limitations, mutagenesis approaches
have shown unequivocal efficiency in identifying or validating
several phosphorylated residues on CXCR4 (Orsini et al., 1999;
Mueller et al., 2013) in combination with a radioactive-labeling
method or use of phospho-specific antibodies. Furthermore,
mutating all the serine and threonine residues to alanine in the
ACKR3C-terminus abolishedb-arrestin recruitment and receptor
internalization, suggesting that receptor trafficking depends on
the phosphorylation of some of these residues (Canals et al., 2012).
Phospho-Specific Antibody. To be able to detect and
assess phosphorylation of residues in cells or tissues, antibodies
that specifically target previously identified phosphorylated
residues of GPCRs can be generated by immunizing animals
with purified synthetic phosphorylated peptides encompassing
the phosphorylated residues (Chen et al., 2013). After selection
and functional validation, those antibodies can be used in
Western blot or immunohistochemistry experiments. Phos-
phorylation can also be indirectly detected using antibodies
specific to the unphosphorylated GPCR, showing decreased
binding to the target when residues are phosphorylated, and
recovery of the binding by using a protein phosphatase to
dephosphorylate the receptor (Hoffmann et al., 2012). Anti-
bodies that recognize several CXCR4 phosphorylated residues
[Ser324/325, Ser330, Ser339, Ser338/339, and Ser346/347 (Woerner
et al., 2005; Busillo et al., 2010; Mueller et al., 2013)] have been
generated and used to investigate the receptor phosphorylation
status in various conditions. To our knowledge, such phospho-
specific antibodies are still lacking for ACKR3.
Association of CXCR4 and ACKR3 with Canonical GPCR-
Interacting Proteins
G proteins, GRKs, and b-arrestins are the protein families
considered canonical GPCR-interacting proteins controlling
receptor activity or being involved in signal transduction.
GPCR activity is a result of a tightly regulated balance
between activation, desensitization, and resensitization
events. After receptor activation and interaction with G
proteins, several mechanisms integrate to trigger GPCR
desensitization and/or modulate additional signaling cas-
cades, including phosphorylation by GRKs and recruitment
of b-arrestins (Penela et al., 2010b; Nogués et al., 2018).
G Proteins. CXCR4 is known to couple to the pertussis
toxin–sensitive Gai protein family that mediates most of its
signaling pathways (Busillo and Benovic, 2007). However,
CXCR4 can also couple to other G proteins such as Ga12/13
(Tan et al., 2006; Kumar et al., 2011) and Gaq (Soede et al.,
2001). Tan and colleagues (2001) observed that both Gai
and Ga13, as well as Gbg subunits are involved in the
CXCL12-dependent migration of Jurkat T cells. Specifically,
Gai proteins promote migration through the activation of Rac,
whereas Ga12/13 proteins activate Rho. Though CXCR4 is
coupled to both Ga12/13 and Gai proteins in Jurkat cells, such a
dual coupling has not been observed in other cell lines where
the receptor specifically activates one or the other G protein
family (Yagi et al., 2011). In fact, pertussis toxin inhibited the
migration of nonmetastatic breast cancer cells (MCF-7), in-
dicating that Gai activation is required. However, it did not
prevent themigration of metastatic breast cancer cells such as
MDA-MB-231 and SUM-159. In those cell lines, Ga12/13
activation mediates CXCL12-induced migration via the acti-
vation of the Rho signaling axis (Yagi et al., 2011). Therefore,
CXCR4 coupling to one or the other G protein family might
depend on the abundance of GPCRs, G proteins, and down-
stream targets.
As an atypical chemokine receptor, ACKR3 lacks the DRY-
LAIV (Asp-Arg-Tyr-Leu-Ala-Ile-Val) motif necessary for inter-
action with G proteins. Nevertheless, using BRET, a study
showed interaction of the receptor with G proteins in trans-
fected HEK293 cells (Levoye et al., 2009). Yet, this interaction
did not lead to the activation of G proteins (Levoye et al., 2009),
reinforcing the common consensus that ACKR3 is unable to
activate G proteins. Consistently, other studies showed that
ACKR3 signals independently of G proteins through a mecha-
nism requiring b-arrestins (Rajagopal et al., 2010; Canals et al.,
2012).
Although these findings clearly indicate that ACKR3 cannot
activate G proteins inmost of the cell types, a report suggested
that ACKR3 might activate G proteins in two specific cellular
contexts, namely primary rodent astrocytes and human
glioma cells (Ödemis et al., 2012). Using [35S]GTPgS-binding
assay, calcium mobilization, and pertussis toxin-dependent
activation of downstream signaling pathways [extracellular
signal–regulated kinases (ERKs 1/2 and AKT phosphoryla-
tion), this group showed an ACKR3-dependent activation of
Gai/o proteins in primary astrocytes (Ödemis et al., 2012).
They also reported pertussis toxin-dependent migration, pro-
liferation, and activation of downstream signaling effectors in
two human glioma cell lines (A764 and U343), further
suggesting an ACKR3-dependent activation of Gai/o. So far,
this is the only report suggesting a possible coupling of ACKR3
with G proteins. Though these data must be further con-
firmed, one possibility is that such a coupling is cell type–
specific. Since ACKR3 was shown to form a heterodimer with
CXCR4 in transfected cell lines (Levoye et al., 2009) and
CXCR4 is well known for its coupling with G proteins (vide
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supra), the authors also investigated the possibility that the
ACKR3-dependent activation of Gai/o proteins was mediated
by the ACKR3/CXCR4 complex. However, constitutive sup-
pression of CXCR4 expression in primary astrocytes did not
influence the ability of ACKR3 to activate G proteins in the
[35S]GTPgS-binding assay (Ödemis et al., 2012). Consistently,
transient suppression of CXCR4 expression did not influence
the ACKR3-dependent calcium mobilization in primary cul-
tures of astrocytes. This suggests that ACKR3 coupling to G
proteins in astroglial cells, if any, occurs independently of the
ACKR3/CXCR4 complex assembly.
Although in that specific case CXCR4 did not influence
ACKR3 signaling, accumulating evidence supports the hy-
pothesis that ACKR3 might conversely influence CXCR4
signaling. Specifically, the organization of CXCR4 andACKR3
in heterodimers appears to inhibit CXCR4 interaction with G
proteins in transfected HEK293T cells, as assessed by satu-
ration BRET (Levoye et al., 2009). In accordance with a
possible influence of ACKR3 on CXCR4-dependent Gai acti-
vation, Sierro and colleagues (2007) showed that the coex-
pression of ACKR3 with CXCR4 hindered the fast and G
protein-dependent ERK activation triggered by CXCL12
exposure. In spite of these observations demonstrating that
ACKR3 influences CXCR4-dependent G protein signaling, a
direct proof of the role of the physical interaction between both
receptors is still missing.
GRKs. Agonist-occupied GPCRs are specifically phosphory-
lated by different GRKs, a family of seven serine/threonine
kinases (Ribas et al., 2007; Penela et al., 2010a). GRKs 2, 3, 5,
and 6 phosphorylate CXCR4 in the C-terminus, which contains
15 serine and three threonine residues that are potential
phosphorylation sites (Fig. 1). At least six of these residues
were shown to be phosphorylated following receptor activation
by CXCL12 (Busillo et al., 2010; Barker and Benovic, 2011;
Mueller et al., 2013). In HEK293 cells, Ser321, Ser324, Ser325,
Ser330, Ser339, and two sites between Ser346 and Ser352 were
shown to be phosphorylated in response to CXCL12 in the
CXCR4 C-terminus using LC-MS/MS and phosphosite-specific
antibodies (Busillo et al., 2010). GRK6 is able to phosphorylate
Ser324/5, Ser339 and Ser330, the latter with slower kinetics,
whereas GRK2 and GRK3 phosphorylate residues between
Fig. 2. CXCR4 C-terminus phosphosites. Schematic representation of the
C-terminal tail of CXCR4, in which serine residues known to be phosphor-
ylated are highlighted in light blue. The kinases or the extracellular
stimuli responsible for the phosphorylation are also specified. Hrg,
heregulin.
Fig. 1. CXCR4 and ACKR3 residues potentially subjected to post-translational modifications. Schematic representation of the C-terminal tail of CXCR4
and ACKR3, in which serine/threonine (red), tyrosine (green), and lysine (blue) residues potentially subjected to post-translational modifications are
highlighted.
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Ser346 and Ser352 (Fig. 2) (Busillo et al., 2010), and specifically
Ser346/347 (Mueller et al., 2013). Interestingly, the latter study
suggested a hierarchy in such phosphorylation events, since
Ser346/347 phosphorylation is achieved faster and is needed for
the subsequent phosphorylation of Ser338/339 and Ser324/325.
Notably, ligand washout resulted in rapid Ser324/325 and
Ser338/339 dephosphorylation, whereas Ser346/347 residues did
not exhibit major dephosphorylation during the 60-minute
period studied (Mueller et al., 2013). Phosphorylation of CXCR4
by different GRKs can elicit several molecular responses, such
as fluctuations in intracellular calcium concentration and
phosphorylation of ERKs 1 and 2, leading to integrated cellular
responses. In HEK293 cells, calcium mobilization is negatively
regulated byGRK2, GRK6, andb-arrestin2. On the other hand,
GRKs 3 and 6 together with b-arrestins act as positive
regulators of ERK1/2 (Busillo et al., 2010). Overall, these
studies show nonoverlapping roles for the different GRKs in
the regulation of CXCR4 signaling. These differential rolesmay
explain distinct cell type–dependent responses to CXCL12.
However, what dictates the specific GRK subtype recruitment
still needs to be investigated. Changes in the normal CXCR4
phosphorylation pattern as a result of receptor mutations or
altered GRK activity can lead to abnormal receptor expression
and/or responsiveness that promotes aberrant cell signaling
and thus can contribute to several pathologies. Deletion of
Ser346/347 leads to a gain of CXCR4-function and decreases
receptor internalization and subsequent desensitization, in-
dicating that mutations in the far C-terminus affect CXCR4-
mediated signaling (Mueller et al., 2013). In this regard, a
subpopulation of patients affected by WHIM (warts, hypogam-
maglobulinemia, infections, and myelokathexis) syndrome, a
rare primary immunodeficiency disease, display C-terminally
truncated CXCR4, leading to refractoriness to desensitization
and enhanced signaling (Balabanian et al., 2008). On the
contrary, increased CXCR4 phosphorylation at Ser339 is asso-
ciated with poor survival in adults with B-cell acute lympho-
blastic leukemia and correlates with poor prognosis in acute
myeloid leukemia patients (Konoplev et al., 2011; Brault et al.,
2014). Altered GRK expression/activity can also impair CXCR4
phosphorylation patterns. GRK3 suppressionmay contribute to
abnormally sustained CXCR4 signaling in classic types of
glioblastoma (Woerner et al., 2012), some WHIM patients
(Balabanian et al., 2008), and in triple negative breast cancer,
thus potentiating CXCR4-dependent migration, invasion, and
metastasis (Billard et al., 2016; Nogués et al., 2018). It is
interesting to note that, although GRKs 2 and 3 share a high
homology and are able to phosphorylate the same residues in
CXCR4 inmodel cells, their function is not redundant.Whereas
both CXCR4 and GRK2 levels are increased in breast cancer
patients, GRK3 is decreased, suggesting a differential role for
both GRKs in a cancer context (Billard et al., 2016; Nogués
et al., 2018). In fact, deregulation of GRK2 potentiates several
malignant features of breast cancer cells, and its level positively
correlates with tumor growth and increased metastasis occur-
rence (Nogués et al., 2016), but whether these roles involve
changes in CXCR4 modulation is still under investigation. On
the other hand, impaired chemotaxis of T and B cells toward
CXCL12 is noted in the absence of GRK6, whereas GRK6
deficiency potentiates neutrophil chemotactic response to
CXCL12 (Fong et al., 2002; Vroon et al., 2004), suggesting that
the occurrence of highly cell type–specific mechanisms in the
control of the CXCL12-CXCR4-GRK6 axis. Overall, these data
indicate the complexity of CXCR4 modulation by GRKs and
support the need for a better characterization of cell type– or
disease-specific CXCR4-GRKs interactions.
ACKR3 has lately been the focus of many studies, in
particular because of its role in cancer progression and
metastasis. However, the mechanisms underlying its regula-
tion are still not well understood, although this receptor has
been shown to interact with GRKs and arrestins and to
associate with other partners. The C-terminus of ACKR3
contains five serine and four threonine residues that can
potentially be phosphorylated (Fig. 1). Unlike for CXCR4,
little is known about their actual phosphorylation status
during the activation of the receptor, as no mass spectrometry
data are available to date and only few mutational studies
have been conducted (Canals et al., 2012; Hoffmann et al.,
2012). In fact, only one study conducted in astrocytes showed
that ACKR3 is phosphorylated by GRK2, but not other GRKs,
and that this phosphorylation is essential for subsequent
ACKR3-operated activation of ERK1/2 and AKT pathways
(Lipfert et al., 2013). This study suggests that ACKR3 is
indeed phosphorylated by GRKs, but the isoform(s) involved
and subsequent responses are probably cell type–dependent
and remain to be investigated in detail.
Arrestins. A study revealed that site-specific phosphory-
lation of CXCR4 by GRK isoforms has contrasting effects upon
b-arrestin recruitment: Although receptor phosphorylation at
its extreme C-terminus [two residues between Ser346 and
Ser352 (Busillo et al., 2010), and specifically Ser346/347 (Mueller
et al., 2013)] by GRK2/3 is a necessary step in b-arrestin
binding; its phosphorylation by GRK6 at upstream residues
[Ser324/5, Ser330, and Ser339 (Busillo et al., 2010)] appears to
inhibit arrestin recruitment to CXCR4 or results in a recep-
tor/arrestin complex that adopts a conformation that is
distinct from that induced by phosphorylation of extreme
C-terminal residues (Oakley et al., 2000; Busillo et al., 2010;
Mueller et al., 2013). Further supporting the importance of
Ser324/5 and Ser339 phosphorylation in b-arrestin recruitment,
CXCR4 truncation mutants showing impaired phosphoryla-
tion at Ser324/325 and Ser338/339 also exhibit reduced CXCL12-
induced receptor internalization (Mueller et al., 2013).
b-arrestins are also scaffold proteins for several signaling
molecules, thus eliciting additional b-arrestin-dependent sig-
naling pathways (Shenoy and Lefkowitz, 2011; Peterson and
Luttrell, 2017). Following the recognition of b-arrestin-
dependent signaling, the notion of biased ligands that prefer-
entially induce G protein-dependent or independent signaling
has emerged (Reiter et al., 2012). Biased signaling at chemo-
kine receptors has been exhaustively reviewed elsewhere
(Steen et al., 2014). For instance, a CXCR4-derived pepducin,
ATI-2341, acts as a biased CXCR4 agonist that promotes Gai
signaling but not b-arrestin signaling, in contrast to CXCL12,
which activates both G protein-dependent and independent
pathways (Quoyer et al., 2013; Steen et al., 2014).
Upon activation by its cognate ligands, CXCL11 andCXCL12,
ACKR3 recruits b-arrestin2 both in vitro (Rajagopal et al., 2010;
Benredjem et al., 2016) and in vivo (Luker et al., 2009), a process
leading to receptor internalization (Canals et al., 2012), trans-
port to lysosomes, and degradation of the receptor-bound chemo-
kine (Luker et al., 2010; Naumann et al., 2010; Hoffmann et al.,
2012). The receptor is then mainly recycled back to the plasma
membrane (Luker et al., 2010) even if a partial degradation of
ACKR3 can be observed (Hoffmann et al., 2012). Interestingly,
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the rate of receptor internalization is faster and recycling is lower
in the presence of CXCL11, compared with CXCL12 (Montpas
et al., 2018).
As previously mentioned, systematic mutation of C-terminal
serine/threonine residues to alanine abolished ligand-induced
b-arrestin2 recruitment to ACKR3, as monitored by BRET
(Canals et al., 2012) and decreased ACKR3 internalization and
subsequent degradation of radiolabeled CXCL12 in HEK293
cells (Hoffmann et al., 2012). Selective mutations of the two
C-terminal serine/threonine clusters to alanine revealed differ-
ences in their functional properties. Mutating Ser335, Thr338,
and Thr341 (first cluster) or Ser350, Thr352, and Ser355 (second
cluster) to alanine decreasedCXCL12 internalization only after
a 5-minute challenge but not following longer agonist receptor
stimulation. Yet, only mutation of the second cluster prevented
CXCL12 degradation. Furthermore, ACKR3 appears to un-
dergo ligand-independent internalization to a much greater
extent than CXCR4 (Ray et al., 2012), and residues 339–362
(the two serine/threonine clusters) are essential for this
peculiar cell fate in HEK293 cells. Although numerous studies
have shown that ACKR3 internalization and the resulting
chemokine degradation are dependent on b-arrestin, recent
findings have been challenging this consensus (Montpas et al.,
2018). Specifically, this study shows that b-arrestins are
dispensable to chemokine degradation, suggesting that other
scaffold proteins might be involved in this process.
Association of CXCR4 with Noncanonical GPCR-Interacting
Proteins
Functional Interaction of CXCR4 with Second
Messenger–Dependent Kinases and Receptor Tyrosine
Kinases. Accumulating evidence indicates that phosphoryla-
tion of GPCRs by second messenger–dependent kinases such as
protein kinase A and protein kinase C (PKC) (Lefkowitz, 1993;
Ferguson et al., 1996;Krupnick andBenovic, 1998), aswell as by
members of the receptor tyrosine kinase family (Delcourt et al.,
2007), participates in the regulation of GPCR signaling. CXCR4
is phosphorylated by PKC at Ser324/5 upon CXCL12 stimulation
(Busillo et al., 2010), and this kinase has also been involved in
Ser346/7 phosphorylation (Luo et al., 2017), even though these
results are not entirely consistent with a previous study using
different PKC inhibitors (Mueller et al., 2013). In some glioblas-
toma cell types, CXCR4 is phosphorylated at Ser339 in response
to the PKC activator phorbol myristate acetate (Woerner et al.,
2005). This suggests that Ser339 is also a PKC phosphorylation
site, and that this phosphorylation event may serve as a
crosstalk mechanism between CXCR4 and GPCRs that activate
Gaq-PKC signaling. Sphingosine 1-phosphate receptors, neuro-
kinin-1 and lysophosphatidic acid receptors may possibly be
involved in glioblastoma progression via this means (Cherry
and Stella, 2014). Nevertheless, the functional impact of Ser339
phosphorylation in glioblastoma remains to be established.
Likewise, epidermal growth factor (EGF) through activation of
its receptor can also promote CXCR4 phosphorylation at Ser339
in glioblastoma cells (Woerner et al., 2005), and both EGF and
heregulin trigger Ser324/325 and Ser330 phosphorylation in the
breast cancer T47D cell line (Sosa et al., 2010). Interestingly, in
MCF7 breast cancer cells, heregulin also promotes CXCR4
phosphorylation on tyrosine residues via epidermal growth
factor receptor (EGFR), leading to b-arrestin2 association with
CXCR4 and downstream activation of the PRex1/Rac1 axis.
However, it is still unclear whether the EGFR-CXCR4 func-
tional interaction is direct or depends on other kinases (Sosa
et al., 2010). In another breast cancer line, BT-474, CXCR4 is
phosphorylated on tyrosine residues in response toCXCL12 and
through activation of ErbB2/ErbB3 and EGFR (Sosa et al.,
2010). Although the specific Tyr residue(s) phosphorylated were
not identified, it is worth noting that CXCR4 displays four
intracellular Tyr residues (Ahr et al., 2005). Tyr157 in the third
intracellular loop has been be involved in CXCR4-dependent
STAT3 signaling (Ahr et al., 2005), whereas Tyr135, within the
conserved DRY motif, might be involved in receptor coupling to
G proteins (Rovati et al., 2007). Consistent with this hypothesis,
EGFR-mediated phosphorylation of the equivalent Tyr in
another GPCR (the m-opioid receptor) has been reported to
reduce coupling to G proteins (Clayton et al., 2010). Therefore,
identification of tyrosine residues phosphorylated in CXCR4
might add some insight into the mechanisms by which growth
factor–receptor tyrosine kinases modulate CXCR4 activity. The
crosstalk between CXCR4 and ErbB2/ErbB3 and EGFR re-
mains an interesting avenue for future research, given the
involvement of both receptors in cancer.
Physical Interaction with Noncanonical GPCR-
Interacting Proteins. Beside canonical GIPs, CXCR4 has
been shown to interact with additional proteins that modulate
CXCR4 trafficking, subcellular localization and signaling, and
proteins whose functions are still unknown. CXCR-interacting
proteins, the methods used for the identification of these
proteins, the site of their interaction in the receptor sequence,
and their functional impact are summarized in Table 2.
Proteins controlling CXCR4 localization or trafficking. Fil-
amin A directly interacts with CXCR4 and stabilizes the
receptor at the plasma membrane by blocking its endocytosis
(Gómez-Moutón et al., 2015). CXCR4 association with the E3
ubiquitin ligase atrophin–interacting protein 4 (AIP4) has
opposite consequences: ubiquitination of CXCR4 by AIP4
targets the receptor tomultivesicular bodies, which is followed
by receptor degradation. In addition, agonist treatment
increases CXCR4/AIP4 interaction, as assessed by Co-IP and
FRET experiments (Bhandari et al., 2009), indicating that this
interaction is dynamically regulated by a receptor conforma-
tional state. In addition, the authors identified Ser324 and
Ser325 as critical sites for the formation of the CXCR4/AIP4
complex upon CXCL12 exposure. The mutation of both
residues to alanine drastically reduces association of AIP4
with CXCR4, whereas their mutation to aspartic acid in-
creases this interaction. Since Ser324/325 are phosphorylated
by GRK6 (Busillo et al., 2010), these results suggest that
CXCR4 activation by CXCL12 triggers recruitment of GRK6,
which in turn phosphorylates the receptor at Ser324/325 to
promote its interaction with AIP4. AIP4 then ubiquitinates
CXCR4 and mediates its degradation (Bhandari et al., 2009).
Reticulon-3 is another CXCR4-interacting protein that pro-
motes its translocation to the cytoplasm (Li et al., 2016).
Proteins modulating CXCR4 signaling and functions. HLA
class II histocompatibility antigen gamma chain (CD74), a
single-pass type II membrane protein that shares with CXCR4
the ability to bind to the macrophage migration inhibitory
factor (MIF), was also shown to interact with CXCR4. The
CXCR4/CD74 complex is involved in AKT activation (Schwartz
et al., 2009). In fact, blocking either CXCR4 or CD74 inhibits
MIF-induced AKT activation. Using FRET, an interaction
between CXCR4 and the Toll-like receptor 2 was observed in
804 Fumagalli et al.
 at A
SPET Journals on February 4, 2020
m
olpharm
.aspetjournals.org
D
ow
nloaded from
 
human monocytes upon activation by Pg-fimbria (fimbriae pro-
duced by the major pathogen associated with periodontitis named
Porphyromonas gingivalis). Analysis of a possible crosstalk be-
tween the two receptors showed that Pg-fimbria directly binds to
CXCR4 and inhibits Toll-like receptor 2–induced nuclear factor-kB
activation by P. gingivalis (Hajishengallis et al., 2008; Triantafilou
et al., 2008). In Jurkat cells, endolyn (CD164) coprecipitates
with CXCR4 in the presence of CXCL12 presented on fibronectin
(Forde et al., 2007). CXCR4-CD164 interaction participates in
CXCL12-induced activation of AKT and protein kinase C zeta
(PKCz). In fact, the downregulation of CD164 reduces the
activation of both kinases measured upon exposure of Jurkat
cells to CXCL12. CXCR4/CD164 interaction has been detected
in additional cell lines, such as primary human ovarian surface
epithelial cells stably expressing CD164 (Huang et al., 2013).
The ability of CXCR4 to promote cell migration requires
deep cytoskeletal rearrangements that can be modulated by
CXCR4-interacting proteins. In Jurkat J77 cells, CXCR4
constitutively associates with drebrin (Pérez-Martínez et al.,
2010), a protein known to bind to F-actin and stabilize actin
filaments. Drebrin is also involved in CXCR4- and CD4-
dependent HIV cellular penetration (Gordón-Alonso et al.,
2013). CXCR4 interacts with diaphanous-related formin-2
(mDIA2). This interaction induces cytoskeletal rearrange-
ments that lead to nonapoptotic blebbing. mDIA2-CXCR4
interaction is only detected during nonapoptotic amoeboid
blebbing and is confined to nonapoptotic blebs upon CXCL12
stimulation (Wyse et al., 2017), suggesting a fine spatiotem-
poral regulation of the interaction. CXCR4 also constitutively
associates with the motor protein nonmuscle myosin H chain
(NMMHC) via its C-terminus (Rey et al., 2002). The authors
showed that NMMHC and CXCR4 are colocalized in the
leading edge of migrating lymphocytes, suggesting that this
association might have a role in lymphocyte migration. The
PI3-kinase isoform p110g coprecipitates with CXCR4 in
CXCL12-stimulated human myeloid cells. This interaction
contributes to receptor-operated integrin activation and che-
motaxis of myeloid cells (Schmid et al., 2011). Finally, CXCR4
was found to be part of a junctional mechano-sensitive
complex through its interaction with the platelet endothelial
cell adhesion molecule (PECAM-1) (dela Paz et al., 2014).
Proteins with unknown functions. Other potential CXCR4-
interacting proteins have been identified using unbiased meth-
ods. These include the lysosomal protein cation-transporting
ATPase ATP13A2 (Usenovic et al., 2012) and the nuclear
protein Myb-related protein B that is involved in cell cycle
progression (Wang et al., 2011). In a study aimed at charac-
terizing the human interactome by Co-IP of 1125 green
fluorescent protein–tagged proteins and LC-MS/MS analy-
sis, CXCR4 was found to coprecipitate with the potassium
channel subfamily K member 1, the CSC1-like protein 2, and
the vesicle transport protein GOT1B (Hein et al., 2015). In
another study, CXCR4 was found to interact with the
eukaryotic translation initiation factor 2B complex in an
acute lymphoblastic leukemia cell line (pre-B NALM-6 cells)
but not in primary lymphocytes (Palmesino et al., 2016). The
interaction was negatively regulated by CXCL12 exposure
and confirmed by colocalization analysis. The same study
showed that CXCR4 recruits parafibromin, SH2 domain
binding protein, hypothetical protein PD2, nucleophosmin,
cyclin-dependent kinase 11B, receptor-type tyrosine-protein
phosphatase S and galectin (Palmesino et al., 2016).
Association of ACKR3 with Noncanonical GPCR-Interacting
Proteins
Unlike for CXCR4, only few proteins are described as
ACKR3-interacting proteins. Given the described role of
ACKR3 in cancer, several studies have addressed ACKR3
crosstalk with well known pro-oncogenic growth factor recep-
tors. ACKR3 colocalizes with and phosphorylates EGFR in
breast and prostate cancer cells (Singh and Lokeshwar, 2011;
Salazar et al., 2014; Kallifatidis et al., 2016), via cell type–
specific mechanisms. However, a potential role for EGFR in
ACKR3 crossactivation was not assessed in these studies.
Some reports also suggest a possible functional interaction
between ACKR3 and transforming growth factor beta (Rath
et al., 2015) or vascular endothelial growth factor (Singh and
Lokeshwar, 2011) receptors, but whether they involve phys-
ical interaction with ACKR3 and/or ACKR3 phosphorylation
and activation was not assessed. ACKR3 weakly interacts
with the MIF receptor CD74 (Alampour-Rajabi et al., 2015).
Moreover, ACKR3 colocalizes with PECAM-1, the cell adhe-
sion molecule required for leukocyte transendothelial migra-
tion in human coronary artery endothelial cells (dela Paz
et al., 2014). Using a membrane yeast two-hybrid assay
screen, cation-transporting ATPase ATP13A2 was identified
as a putativeACKR3-interactingprotein (Usenovic et al., 2012).
In the study aimed at characterizing the human interactome of
1125 green fluorescent protein–tagged proteins, ACKR3 was
found to interact with the gap junction b-2 protein, the 54S
ribosomal protein L4, 54S ribosomal protein L4, mitochondrial
(MRPL4), different ATP synthases (ATP5H, ATP5B, ATP5A1,
ATP50), ACKR3 itself, the caspase separin ESPL1, the proba-
ble E3 ubiquitin-protein ligase HECTD2, and the putative E3
ubiquitin-protein ligase UBR7 (Hein et al., 2015). Ubiquitina-
tion is an essentialmechanismof receptor regulation (Marchese
and Benovic, 2001; Shenoy, 2007). ACKR3 can undergo ubiq-
uitination in an agonist-dependent and -independent manner
to regulate receptor trafficking. Ubiquitination is promoted by
three enzymes, E1, E2, and E3, that ubiquitinate proteins on
lysine residues (Dores and Trejo, 2012; Alonso and Friedman,
2013). Unexpectedly, ACKR3 is ubiquitinated by E3 ubiqui-
tin ligase (E3) in the absence of an agonist and undergoes
deubiquitination upon CXCL12 activation (Canals et al., 2012).
Mutation of the five lysines in the receptor C-terminus to
alanine, to prevent ubiquitination, impaired ACKR3 cell-
trafficking and decreased ACKR3-mediated CXCL12 degrada-
tion (Hoffmann et al., 2012).
Conclusions
The identification of GPCR-interacting proteins and residues
subjected to post-translational modification is of utmost impor-
tance. Several techniques are currently available to decipher
the GPCR interactome and phosphorylation profile. These
techniques have been successfully applied to CXCR4, revealing
important interacting proteins as well as key residues involved
in the regulation of receptor-mediated signal transduction. In
contrast, ACKR3 interactome and phosphorylation sites have
not been systematically investigated. Unbiased studies of the
ACKR3 interactome and its phosphorylated residues and their
control by ACKR3 ligands should open new avenues in the
understanding of ACKR3 pathophysiological functions and the
underlying signaling mechanisms.
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